Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors
Vignesh ShanmugamiD, Neriman TokcaniD, Daniel ChafamoiD, Sean SullivaniD, Mehdi BorjiiD, Haley K. Martin, Gail A. Newton, Naeem M. NadafiD, Saoirse Hanbury, Irving BarreraiD, Dylan M. CableiD, Jackson A. WeiriD, Orr AshenbergiD, Geraldine Pinkus, Scott J. RodigiD, Caroline UhleriD, Evan Z. MacoskoiD, Margaret Ann ShippiD, Abner LouissaintiD, Fei CheniD, Todd R. GolubiD
Abstract
A key challenge in cancer research is to identify the secreted factors that contribute to tumor cell survival. Nowhere is this more evident than in Hodgkin lymphoma, where malignant Hodgkin Reed Sternberg (HRS) cells comprise only 1-5% of the tumor mass, the remainder being infiltrating immune cells that presumably are required for the survival of the HRS cells. Until now, there has been no way to characterize the complex Hodgkin lymphoma tumor microenvironment at genome scale. Here, we performed genome-wide transcriptional profiling with spatial and single-cell resolution. We show that the neighborhood surrounding HRS cells forms a distinct niche involving 31 immune and stromal cell types and is enriched in CD4+ T cells, myeloid and follicular dendritic cells, while being depleted of plasma cells. Moreover, we used machine learning to nominate ligand-receptor pairs enriched in the HRS cell niche. Specifically, we identified IL13 as a candidate survival factor. In support of this hypothesis, recombinant IL13 augmented the proliferation of HRS cells in vitro. In addition, genome-wide CRISPR/Cas9 loss-of-function studies across more than 1,000 human cancer cell lines showed that IL4R and IL13RA1, the heterodimeric partners that constitute the IL13 receptor, were uniquely required for the survival of HRS cells. Moreover, monoclonal antibodies targeting either IL4R or IL13R phenocopied the genetic loss of function studies. IL13-targeting antibodies are already FDA-approved for atopic dermatitis, suggesting that clinical trials testing such agents should be explored in patients with Hodgkin lymphoma.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 7
- FWCI
- 4.66
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The spatially resolved tumor microenvironment predicts treatment outcome in relapsed/refractory Hodgkin lymphoma
- Single cell spatial analysis and biomarker discovery in Hodgkin lymphoma
A. M. Xu, A. Jiang, … A. Merchant·bioRxiv·May 24, 2023
- Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response
Mikhail Roshal, Isabella Y. Kong, … Ethel Cesarman·Blood Cancer JournalPeer-reviewed·Apr 22, 2026
- LSD1 inhibition corrects dysregulated MHC-I and dendritic cells activation through IFNγ-CXCL9-CXCR3 axis to promote antitumor immunity in HNSCC
Amit Kumar Chakraborty, Lina Kroehling, … Manish V. Bais·bioRxiv·Mar 17, 2025
- Tertiary lymphoid structures induced by CXCL13-producing CD4+ T cells increase tumor infiltrating CD8+ T cells and B cells in ovarian cancer
M. Ukita, J. Hamanishi, … M. Mandai·JCI InsightPeer-reviewed·Jun 22, 2022
- Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma
G. Gaglia, M. Burger, … S. Santagata·bioRxiv·Aug 11, 2022